Psychoseprävention jetzt in die klinische Versorgung einführen!

Präventive Ansätze haben die Prognose einer Reihe von Volkserkrankungen wie z. B. arterieller Hypertonie oder Diabetes mellitus wesentlich verbessert. Damit der Einsatz eines präventiven Ansatzes zur Verhinderung des Auftretens einer Erkrankung in die klinische Regelversorgung gerechtfertigt ist, müssen 2 Voraussetzungen erfüllt sein: Erstens, muss die Identifikation eines Risikostadiums mit klinisch bedeutsamer Gefahr des Übergangs in das volle Erkrankungsbild möglich sein. Zweitens, müssen Interventionen vorliegen, die dieses Übergangsrisiko bei angemessen Nebenwirkungen in klinisch bedeutsamer Weise reduzieren.

• Literatur

• 1 van Os J, Kapur S. Schizophrenia. Lancet 2009; 374: 635-645
• 2 Konnopka A, Klingberg S, Wittorf A et al. The cost of schizophrenia in Germany: a systematic review of the literature. Psychiat Prax 2009; 36: 211-218
• 3 Yung AR, Phillips LJ, Yuen HP et al. Psychosis prediction: 12-month follow up of a high-risk (“prodromal”) group. Schizophr Res 2003; 60: 21-32
• 4 Klosterkotter J, Hellmich M, Steinmeyer EM et al. Diagnosing schizophrenia in the initial prodromal phase. Arch Gen Psychiatry 2001; 58: 158-164
• 5 Miller TJ, McGlashan TH, Rosen JL et al. Prospective diagnosis of the initial prodrome for schizophrenia based on the Structured Interview for Prodromal Syndromes: preliminary evidence of interrater reliability and predictive validity. Am J Psychiatry 2002; 159: 863-865
• 6 Yung AR, Yuen HP, McGorry PD et al. Mapping the onset of psychosis: the Comprehensive Assessment of At-Risk Mental States. Aust N Z J Psychiatry 2005; 39: 964-971
• 7 Fusar-Poli P, Bonoldi I, Yung AR et al. Predicting psychosis: meta-analysis of transition outcomes in individuals at high clinical risk. Arch Gen Psychiatry 2012; 69: 220-229
• 8 McGorry PD, Yung AR, Phillips LJ et al. Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Arch Gen Psychiatry 2002; 59: 921-928
• 9 Morrison AP, French P, Walford L et al. Cognitive therapy for the prevention of psychosis in people at ultra-high risk: randomised controlled trial. Br J Psychiatry 2004; 185: 291-297
• 10 Addington J, Epstein I, Liu L et al. A randomized controlled trial of cognitive behavioral therapy for individuals at clinical high risk of psychosis. Schizophr Res 2011; 125: 54-61
• 11 Bechdolf A, Wagner M, Ruhrmann S et al. Preventing progression to first-episode psychosis in early initial prodromal states. Br J Psychiatry 2012; 200: 22-29
• 12 McGlashan TH, Zipursky RB, Perkins D et al. Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am J Psychiatry 2006; 163: 790-799
• 13 Amminger GP, Schafer MR, Papageorgiou K et al. Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Arch Gen Psychiatry 2010; 67: 146-154
• 14 Marshall M, Rathbone J. Early intervention for psychosis. Cochrane Database Syst Rev 2011; DOI: CD004718
• 15 Preti A, Cella M. Randomized-controlled trials in people at ultra high risk of psychosis: a review of treatment effectiveness. Schizophr Res 2010; 123: 30-36
• 16 Muller H, Wiessmann T, Bechdolf A. Interventionen bei Personen mit erhöhtem Psychoserisiko: Eine aktuelle Übersicht über randomisiert kontrollierte Studien . Fortschr Neurol Psychiatr 2012; 80: 570-579
• 17 Phillips LJ, Cotton S, Mihalopoulos C et al. Cost implications of specific and non-specific treatment for young persons at ultra high risk of developing a first episode of psychosis. Early Interv Psychiatry 2009; 3: 28-34
• 18 Kohn D, Pukrop R, Niedersteberg A et al. Pathways to care: help-seeking behavior in first-episode psychosis. Fortschr Neurol Psychiatr 2004; 72: 635-642
• 19 Bechdolf A, Pukrop R, Kohn D et al. Subjective quality of life in subjects at risk for a first episode of psychosis: a comparison with first episode schizophrenia patients and healthy controls. Schizophr Res 2005; 79: 137-143
• 20 Svirskis T, Korkeila J, Heinimaa M et al. Axis-I disorders and vulnerability to psychosis. Schizophr Res 2005; 75: 439-446
• 21 Correll CU, Hauser M, Auther AM et al. Research in people with psychosis risk syndrome: a review of the current evidence and future directions. J Child Psychol Psychiatry 2010; 51: 390-431
• 22 Addington J, Cornblatt BA, Cadenhead KS et al. At clinical high risk for psychosis: outcome for nonconverters. Am J Psychiatry 2011; 168: 800-805
• 23 American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. DSM-IV. 4th. Edition. Arlington: American Psychiatric Association; 2000
• 24 American Psychiatric Association. DSM-5 Development. 2011 http://www.dsm5.org/Pages/Default.aspx
• 25 Gaebel W, Reed GM. Status of Psychotic Disorders in ICD-11. Schizophr Bull 2012; 38: 895-898
• 26 Bechdolf A, Peukert R. Psychosis prevention: expectations met. Psychiat Prax 2011; 38: 58-60
• 27 Hauser M, Lautenschlager M, Gudlowski Y et al. Psychoeducation with patients at-risk for schizophrenia – an exploratory pilot study. Patient Educ Couns 2009; 76: 138-142
• 28 Zarafonitis SWM, Pützfeld V, Berning J et al. Psychoedukation bei Personen mit erhöhtem Psychoserisiko. Psychotherapeut 2012; 57: 326-334
• 29 DeLisi L. Schizophrenia Research 2001; 51
• 30 Häfner H, Bechdolf A, Klosterkötter J et al. Psychosen – Früherkennung und Frühintervention. Stuttgart: Schattauer; 2012
• 30 Australia Medical Association. A Ten Year Roadmap for National Mental Health. 2012 https://ama.com.au/submission-draft-ten-year-roadmap-national-mental-health-reform